title: Thrombotic thrombocytopenic purpura in southern Turkey: a single-center experience of 29 cases.
abstract: In this retrospective, nonrandomized study, we describe our experience in the management of 29 consecutive patients with thrombotic thrombocytopenic purpura (TTP) treated with a combined therapy of plasma exchange (PE) and steroids at a single center. We compared the effectiveness of high-dose steroids (20-25 mg/kg methyl prednisolone) as first-line treatment in combination with PE therapy with the combination of standard-dose steroids (1 mg/kg methyl prednisolone) and PE in adult patients with TTP. Clinical, laboratory data and treatment outcomes such as response rate, median time to recovery and survival were evaluated retrospectively. Overall (OR) and complete (CR) response rates were 69 and 52% respectively. Similar response rates were found in patients treated with pulse or conventional dose steroids; however, the median time to response was delayed in the high-dose methyl prednisolone (HDP) group. The median time from the initiation of symptoms to initiation of treatment was approximately 15 days (range: 0-30). Delayed treatment in our patients because of delayed referral to our center resulted in poor response to treatment. In all, four of 14 (27%) complete responders experienced relapses. The predicted relapse rate was 48% at a median of 30 months. All the relapses presented with a combination of thrombocytopenia and microangiopathic hemolytic anemia. This analysis showed that high-dose steroid treatment did not prove to be beneficial for TTP patients as firstline therapy combined with PE. Moreover, pulse steroid interventions might have resulted in delayed responses and our data suggest that initiation of treatment with PE should not be delayed.
authors.affiliation: Department of Hematology, Cukurova University Medical School, Adana, Turkey. egurkan@cu.edu.tr
authors.forename: E
authors.initials: E
authors.lastname: Gurkan
authors.forename: F
authors.initials: F
authors.lastname: Baslamisli
authors.forename: B
authors.initials: B
authors.lastname: Guvenc
authors.forename: N B
authors.initials: NB
authors.lastname: Kilic
authors.forename: C
authors.initials: C
authors.lastname: Unsal
authors.forename: E
authors.initials: E
authors.lastname: Karakoc
mesh_terms: D000293:Adolescent; D000328:Adult; D019468:Disease Management; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D010951:Plasma Exchange; D011697:Purpura, Thrombotic Thrombocytopenic / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D013256:Steroids / Q000008:administration & dosage; D015996:Survival Rate; D016896:Treatment Outcome; D014421:Turkey
chemical_list: D013256:Steroids; D008775:Methylprednisolone